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Abstract 
Introduction: 
CD103 is a specific integrin present on some CD4+ lymphocytes of the mucosal immune system. It 
has been hypothesized that most CD4+ lymphocytes in pulmonary sarcoidosis do not originate from 
mucosal sites but from redistribution from the peripheral blood, and therefore do not bear the 
CD103 integrin. Several studies have suggested that a low CD103+ percentage among 
bronchoalveolar lavage (BAL) CD4+ lymphocytes discriminates between sarcoidosis and other causes 
of lymphocytic alveolitis, but contradictory data exist. 
Methods: 
We reviewed 1151 consecutive patients with BAL lymphocytosis >10% and flow cytometry 
performed between 2006 and 2014. 944 cases were excluded due to poor BAL quality (n= 97), 
unavailable clinical data (n= 760), or unclear diagnosis (n= 87). The remaining 207 patients were 
grouped into 9 diagnostic categories. To assess the discriminative value of the CD103+CD4+/CD4+ 
ratio to distinguish sarcoidosis from the other entities, area under ROC curves (AUC) were 
determined.  
Results: 
Sarcoidosis patients (n=53) had a lower CD103+CD4+/CD4+ ratio than the other diagnostic 
categories. AUC was 62% for sarcoidosis compared to all other patients and 69% for sarcoidosis 
compared to other interstitial lung diseases. When combining CD103+CD4+/CD4+ and CD4+/CD8+ 
ratios, AUC increased to 76% and 78% respectively. When applying published cut-offs from 4 
previous studies to our population, AUC varied between 54 and 73%. 
Conclusions:  
The CD103+CD4+/CD4+ ratio does not accurately discriminate between sarcoidosis and other causes 
of lymphocytic alveolitis, neither alone nor in combination with CD4+/CD8+ ratio, and is not a 
relevant marker for the diagnosis of sarcoidosis.  
 
  
3 
 
Introduction 
Sarcoidosis is a chronic multi-systemic disease of unknown origin characterized by granulomatous 
inflammation in various organs. It affects the lungs in 90 % of cases, and is the most frequent 
interstitial lung disease with a prevalence of 121/100 000 [1][2]. Diagnosis of pulmonary sarcoidosis 
is based on clinical symptoms, chest imaging, bronchoalveolar lavage (BAL), and histopathology 
obtained by either bronchial biopsy (BB), transbronchial lung biopsy (TBB), more recently 
transbronchial needle aspiration (TBNA), or rarely surgical lung biopsy [3][4][5]. 
Pulmonary sarcoidosis is characterized by increased T-cells in BAL fluid (BALF) compared to healthy 
subjects [6]. These T-cells are predominantly CD4+, with a CD4+/CD8+ ratio typically 3:1 to 5:1 
compared with a ratio of 2:1 in healthy subjects [7]. However, the diagnostic value of BAL in 
sarcoidosis is limited by the lack of a specific and sensitive marker. BAL lymphocytosis is not specific 
of sarcoidosis and the use of CD4+/CD8+ ratio is controversial except when it is higher than 3.5 and 
only if the disease is active [8]. 
Several studies have investigated the CD103 integrin present on some CD4+ lymphocytes as a 
diagnostic marker of sarcoidosis [9][10][11][12]. CD103 is a specific molecule of the mucosal immune 
system [13]. It has been hypothesized that most CD4+ lymphocytes in pulmonary sarcoidosis do not 
originate from mucosal sites, but from redistribution from the peripheral blood, and therefore do not 
possess the CD103 integrin [14]. Kolopp-Sarda et al. were the first to investigate this integrin and 
suggest that a high CD4+/CD8+ ratio combined with a low CD103+/CD4+ ratio may allow to 
distinguish sarcoidosis from other interstitial lung diseases (ILDs) with a 96% sensitivity [9]. Similarly, 
Mota et al. found a 98% sensitivity [10]. However, two other studies showed a low performance of 
CD103+/CD4+ ratio as a diagnostic marker for sarcoidosis [11][12]. The goal of the present study was 
to further investigate the value of the CD103+CD4+/CD4+ ratio to differentiate sarcoidosis from 
other causes of lymphocytic alveolitis in a retrospective case series.  
 
Materials and methods 
Case selection  
The case selection process is summarized in figure 1. 1151 BAL flow cytometries were performed at 
the Pathology Institute of the Lausanne University Hospital between January 1st, 2006 and July 18th, 
2014. Flow cytometry was routinely performed on all BAL samples with >10% lymphocytes on 
differential cell count. 97 cases were excluded due to insufficient technical quality of the BAL sample. 
The electronic medical records of the remaining 1054 cases were reviewed. 760 cases were excluded 
due to unavailable clinical data (mainly because BAL was received from other medical facilities). Of 
the remaining 294 cases, 87 cases were excluded because the final diagnosis was unclear or 
unavailable (n=46), or because pre-defined diagnostic criteria (see below) were not met (n=41). The 
remaining 207 cases were included. 
Pre-defined diagnostic criteria were the following. The diagnosis of sarcoidosis required compatible 
clinical and imaging picture and the presence of non-caseating granuloma on tissue biopsy (n = 22) or 
transbronchial needle aspiration cytology of mediastinal lymph nodes (n = 25). Typical stage I 
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sarcoidosis occurring in the context of Löfgren syndrome without biopsy or cytology was also 
accepted (n=6). The diagnosis of pulmonary tuberculosis required the presence of acid-fact bacilli, 
positive polymerase chain reaction  and/or positive cultures for M. tuberculosis on sputum, bronchial 
aspiration, or BAL (n = 22). A diagnosis of infection other than tuberculosis required either 
identification of a virus or bacteria on sputum, bronchial aspiration, or BAL (n = 23), or marked 
clinical improvement with antibiotic therapy (n = 15). Hypersensitivity pneumonitis (HP) was 
diagnosed according to the criteria of Schuyler et al. (n = 6) [15]. Diagnosis of drug-induced 
pneumonitis was based on a history of exposure to a drug with known pulmonary toxicity, a 
temporal relationship between exposure and onset of symptoms, and improvement after drug 
withdrawal (n = 19). Organizing pneumonia (OP) was diagnosed on the basis of compatible clinical 
and imaging features, and presence of buds of granulation tissue on transbronchial lung biopsy 
without any feature suggesting another diagnosis (n = 5). The diagnosis of OP was also accepted in 
the absence of biopsy if radiation therapy for breast cancer, a classical cause of OP, occurred in the 
past year (n = 4).  Nonspecific interstitial pneumonia (NSIP) was diagnosed on surgical lung biopsy (n 
= 2). A diagnosis of NSIP pattern was also accepted if the clinical and imaging findings were highly 
suggestive even in the absence of surgical lung biopsy (n = 12). 
Cases not meeting the above diagnostic criteria were discarded. These included suspicion of 
sarcoidosis without histological diagnosis (n=13), clinical suspicion of tuberculosis without 
microbiological evidence of M. tuberculosis infection (n=7), clinical suspicion of infection without 
sufficient evidence to support this diagnosis (n=10), and clinical suspicion of OP without histological 
proof (n=11). 
Included cases were grouped into 9 diagnostic categories: sarcoidosis, tuberculosis, non-tuberculous 
infections, HP, NSIP, OP, drug-induced lung diseases, other ILDs, and other diagnoses. As some 
categories had a small number of cases, cases were further grouped into 4 larger categories: 
sarcoidosis, infections (including tuberculosis and non-tuberculous infections), ILDs (including HP, 
NSIP, OP, drug-induced lung diseases, and other ILDs) and other diagnoses. Statistical analysis was 
performed for both the 9-category and 4-category distributions. 
 
Bronchoalveolar lavage and flow cytometry 
BAL fluid was collected during regular diagnostic workup in sterile bottles and filtered through gauze. 
10 ml of the sample were cytocentrifugated then smeared and stained with May-Grünwald Giemsa, 
modified Papanicolaou and Prussian Blue for analysis. For differential cell count, a sample 
corresponding to 250.000-300.000 cells was passed through a multipore filter. After staining with 
modified Papanicolaou, a minimum of 2x100 cells were counted. 
For flow cytometry, 10-30ml of native sample were centrifuged, decanted and resuspended in NH4Cl 
or Roswell Park Memorial Institute medium several times until reaching a cellularity of 2x106. The 
cells were stained with fluorochrome-labelled monoclonal antibodies for CD45, CD3, CD4, CD8, and 
CD103 following a standard protocol and five-color flow cytometric analysis was performed (Navios 
Beckman Coulter flow cytometer). 
 
5 
 
Statistical analysis 
Data analyses were performed using Stata software (StataCorp. 2013. Stata Statistical Software: 
Release 13. College Station, TX: StataCorp LP). Univariable analyses were performed and the results 
expressed as median and interquartile range (IQR) for continuous non-normally distributed variables, 
and as percentages for categorical variables. Bivariable analyses were done using Student’s t-test and 
one-way ANOVA or Kruskal-Wallis tests.  All hypothesis testings were 2-sided and type I error was 
controlled at the 0.05 level. 
ROC curves were used to assess the discriminative power of the cellular marker ratios 
CD103+CD4+/CD4+, CD4+/CD8+  and their combination to distinguish sarcoidosis from other 
diagnoses.  Optimal cut-off value, sensitivity, specificity and precision were determined for each ROC 
curve. 
Results 
Study population 
A total of 207 patients with a confirmed diagnosis were included. The main characteristics of the 
study population are presented in table 1. The mean age was 54 years and 47% were women. 
Patients with sarcoidosis, HP and tuberculosis were significantly younger than patients of other 
diagnostic categories (p=0.0001). BAL neutrophils were significantly lower in sarcoidosis and higher in 
HP and non-tuberculous infections (p=0.0001). No significant differences were found between 
categories for BAL lymphocyte count. 
Analysis of flow cytometry in 9 diagnostic categories  
Results of flow cytometry in the 9-category distribution are presented in table 2. The CD4+/CD8+ 
ratio was significantly higher in sarcoidosis compared to all other diagnoses except for tuberculosis 
(figure 2A). The area under the ROC curve (AUC) to discriminate between sarcoidosis and all other 
diagnoses was 79 % (figure 3A). The cut-off value where specificity and sensitivity of CD4+/CD8+ ratio 
for sarcoidosis were equal (between 69% and 70%) was 3.4.  
The CD103+CD4+/CD4+ ratio was significantly lower in sarcoidosis compared to drug-induced ILDs, 
NSIP and HP (figure 2B). The AUC to discriminate between sarcoidosis and all other diagnoses was 
62% (figure 3B). A combination of CD4+/CD8+ and CD103+CD4+/CD4+ ratios resulted in an AUC of 
76% (figure 3C), which was lower than the AUC of CD4+/CD8+ ratio alone. 
Analysis of flow cytometry in 4 diagnostic categories  
The data was also analysed after grouping cases into 4 large categories: sarcoidosis, all infections, all 
ILDs and others (table 3). CD4+/CD8+ ratio was significantly higher in sarcoidosis compared to each 
other category individually (figure 4A). The only significant difference in the CD103+CD4+/CD4+ ratio 
was between sarcoidosis and ILDs (figure 4B), with a higher ratio in ILD (0.14 vs 0.08, p<0.001). 
The CD4+/CD8+ ratio in sarcoidosis compared to all ILDs had an AUC of 79%, with a cut-off where 
specificity and sensitivity are equal (69-70%) at 3.4. The AUC for the CD103+CD4+/CD4+ ratio was 
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69%. The combination of the CD4+/CD8+ and CD103+CD4+/CD4+ ratios resulted in an AUC of 78%, 
which was lower than that of the CD4+/CD8+ ratio alone (data not shown). 
Validation of cut-off values from previous studies 
4 studies analyzing CD103+CD4+/CD4+ ratio in sarcoidosis have been previously performed 
[9][10][11][12]. The cut-off values defined in these studies to discriminate between sarcoidosis and 
other diagnoses were applied to our study population for comparison (table 4). Sensitivity varied 
between 55% and 98%, and specificity between 9% and 86%. The precision of classification varied 
between 32% and 78%, and the AUC varied between 54% and 73%. 
 
Discussion 
In the present study, we demonstrate that the BAL lymphocyte CD103+CD4+/CD4+ ratio does not 
accurately discriminate between sarcoidosis and other causes of lymphocytic alveolitis, neither alone 
nor in combination with CD4+/CD8+ ratio, and is therefore not a relevant marker for the diagnosis of 
sarcoidosis. Furthermore, the CD103+CD4+/CD4+ ratio does not accurately discriminate between 
sarcoidosis and other ILDs. When applying the previously published CD103+CD4+/CD4+ ratio cut-offs 
to our population, we generally found lower sensitivity and specificity than in the original studies. 
The CD4+/CD8+ ratio has been previously investigated to determine whether it could make an 
accurate diagnosis of sarcoidosis without lung biopsy [7][16][17][18]. In agreement with these data, 
we found a significant correlation between sarcoidosis and an elevated CD4+/CD8+ ratio (>3.4 in our 
study). However, the AUC of the CD4+/CD8+ ratio to distinguish sarcoidosis from other causes of 
lymphocytic alveolitis was only 79%, and it was also 79% to separate sarcoidosis from other ILDs. 
Thus, on its own, this marker cannot differentiate between sarcoidosis and other interstitial lung 
diseases with enough accuracy to be useful in daily practice.  
Four previous studies have investigated the CD103 integrin on CD4+ T-lymphocytes in BAL as a 
putative marker for sarcoidosis [9][10][11][12], and several of them have suggested that a high 
CD4+/CD8+ ratio combined with a low CD103+CD4+/CD4+ ratio would allow to distinguish 
sarcoidosis from other causes of alveolar lymphocytosis. Kolopp-Sarda et al. first reported that the 
combination of a CD4+/CD8+ ratio > 2.5 and a CD103+/CD4+ ratio < 0.31 had a sensitivity of 96% to 
discriminate between sarcoidosis and other causes of lymphocytic alveolitis [9]. These authors 
concluded that the combination of both ratios would constitute a good marker for the diagnostic of 
sarcoidosis.  Heron et al., and Mota et al. also reported a good discriminative power for the 
CD103+CD4+/CD4+ ratio (table 4), and agreed with Kolopp-Sarda’s conclusions [10][12]. However, in 
another study by Hyldegaard et al., the combination of CD4+/CD8+ and CD103+CD4+/CD4+ ratios 
had a sensitivity of only 42% and a specificity of 91%, which led to conclude that the combination of 
these ratios was a poor marker for sarcoidosis. Of note, all these studies had small study populations 
(table 4) and two of them included less than 20 cases of sarcoidosis [9][11]. 
In our population, the CD103+CD4+/CD4+ ratio had a weak discriminative power for the diagnosis of 
sarcoidosis, with an AUC of only 62% to distinguish sarcoidosis from all other causes of lymphocytic 
alveolitis, and an AUC of 69% to distinguish sarcoidosis from other ILDs. The use of combined 
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CD4+/CD8+ and CD103+CD4+/CD4+ ratios resulted in modest increases of the AUC to 76% for 
sarcoidosis versus all causes of lymphocytic alveolitis, and to 78% for sarcoidosis versus other ILDs. 
This remained lower than the AUC of the CD4+/CD8+ ratio alone (79%), suggesting that the 
contribution of the CD103+CD4+/CD4+ ratio itself was low. 
We also tested the cut-off values suggested by other studies on our population (table 4). The highest 
percentage of correctly classified patients (78%) was achieved by using Hyldegaard et al.’s cut-off, 
whereas with the one suggested by Mota et al., the percentage of correctly classified patients was 
very low (32%). Further analysis of our population using the CD103+CD4+/CD4+ ratio alone showed a 
high sensitivity but a very low specificity, and the precision did not exceed 37% (table 4). Altogether, 
this reinforces our own observations suggesting that the CD103+CD4+/CD4+ ratio, either alone or 
combined to the CD4+/CD8+ ratio, does not provide sufficient diagnostic precision to identify 
sarcoidosis among other causes of lymphocytic alveolitis. 
The strong points of our study was the large size of the population (n=207), which was much higher 
than any other study of the CD103+CD4+/CD4+ ratio. The number of sarcoidosis cases (n=53) was 
also higher than most other studies, and almost equaled the 56 cases reported by Heron et al [12]. 
Unlike the other studies, we were able to precisely classify our population in well-defined diagnostic 
categories and compare sarcoidosis to each category individually, as well as to broader diagnostic 
groups. This allowed a more precise analysis of CD103+CD4+/CD4+ ratio for other diagnoses such as 
HP, NSIP,  infections and other ILDs.  
One limitation of our study is that we included only patients with BAL lymphocytosis, whereas there 
have been reports of cases of sarcoidosis without this feature [11][19][20]. However, we believe that 
this occurrence is rare and would have not invalidated our conclusions. Another limitation is that all 
diagnostic categories were not equally represented. For instance, there was only a small number of 
patients with HP in our population.  
Altogether, the hypothesis behind CD103+CD4+/CD4+ ratio in sarcoidosis could very well be true. 
Indeed, all studies demonstrate that there is a lower percentage of CD4+ lymphocytes presenting the 
CD103 integrin in the lungs of patients with sarcoidosis as compared to patients with other illnesses 
causing pulmonary lymphocytosis. However, as demonstrated in the present study, the 
CD103+CD4+/CD4+ ratio does not have enough discriminative power to accurately differentiate 
between sarcoidosis and other disorders causing pulmonary lymphocytosis, and cannot replace lung 
biopsy or lymph node needle aspiration for the diagnosis of sarcoidosis. 
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Legends to figures 
Figure 1:  
Case selection process including the number of excluded cases and the reason for exclusion. HP: 
hypersensitivity pneumonitis, NSIP: nonspecific interstitial pneumonia, OP: organising pneumonia.  
 
Figure 2:  
Box-whiskers plots of CD4+/CD8+ (A) and CD103+CD4+/CD4+ (B) ratios in 9 diagnostic categories. HP: 
hypersensitivity pneumonitis, NSIP: nonspecific interstitial pneumonia, OP: organising pneumonia. 
 
Figure 3: 
ROC curves for CD4+/CD8+ ratio (A), CD103+CD4+/CD4+ ratio (B) and their combination (C) to 
distinguish sarcoidosis from all other diagnoses. 
 
Figure 4: 
Box-whiskers plots of CD4+/CD8+ (A) and CD103+CD4+/CD4+ (B) ratios in 4 diagnostic categories. 
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Table 1: Demographic and BAL characteristics of the study population 
Diagnostic 
category 
n 
age 
(yrs) 
BAL lymphocytes 
(%) 
BAL neutrophils 
(%) 
BAL eosinophils 
(%) 
  
median iqr median iqr median iqr median iqr 
Sarcoidosis 53 46 20 47 29 2 4 0 1 
Tuberculosis 22 37 31 39 18 3 7 0 1 
Other 
infections 
38 61 21 43 28 9 20 0 2 
HP 6 36 37 49 27 24 25 2 2 
NSIP 14 67 13 39 25 4 5 4 7 
OP 9 67 7 47 24 4 10 3 12 
Drug-induced 
pneumonia 
19 71 18 55 34 4 6 1 2 
Other ILD 21 59 23 51 41 7 7 1 3 
Other 
diagnoses 
25 57 19 45 29 4 9 1 1 
Total 207 56 28 45 29 4 9 1 2 
HP: hypersensitivity pneumonitis, NSIP: nonspecific interstitial pneumonia, OP: organising pneumonia; ILD; 
interstitial lung disease, iqr: interquartile range. 
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Table 2: Flow cytometry for the 9-category distribution 
 
CD4+/CD8+ ratio CD103+CD4+/CD4+ ratio 
Diagnostic category median iqr p value* median iqr p value* 
Sarcoidosis 5.3 5.9 - 0.08 0.15 - 
Tuberculosis 2.3 2.5 0.052 0.09 0.11 0.488 
Other infections 1.7 1.9 <0.001 0.09 0.13 0.242 
HP 1.8 3.5 <0.001 0.27 0.61 0.037 
NSIP 0.6 1.4 <0.001 0.21 0.21 0.018 
OP 2.0 2.1 <0.001 0.10 0.09 0.698 
Drug-induced 
pneumonia 1.3 2.9 0.044 0.15 0.16 0.060 
Other ILD 1.6 3.6 0.011 0.14 0.19 0.006 
Other diagnoses 1.6 3.1 0.010 0.10 0.16 0.106 
Total 2.4 3.6   0.10 0.17   
HP: hypersensitivity pneumonitis, NSIP: nonspecific interstitial pneumonia, OP: organising 
pneumonia, ILD: interstitial lung disease, iqr: interquartile range. * compared to sarcoidosis. 
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Table 3: Flow cytometry for the 4-category distribution  
 CD4+/CD8+ ratio  CD103+CD4+/CD4+ ratio  
Diagnostic category median iqr p value* median iqr p value* 
Sarcoidosis 5.3 5.9 - 0.08 0.15 - 
All infections 2.0 2.7 <0.001 0.09 0.12 0.213 
All ILDs 1.5 3.2 <0.001 0.14 0.19 <0.001 
Other diagnoses 1.6 3.1 0.009 0.10 0.16 0.102 
Total 2.4 3.6  0.10 0.17  
ILD: interstitial lung disease. iqr: interquartile range. * compared to sarcoidosis  
 
  
12 
 
Table 4: Comparison to other studies 
Study Cut-off Population Published values  Our population 
   Se 
(%) 
Sp 
(%) 
 Se 
(%) 
Sp 
(%) 
Precision 
(%) 
AUC 
(%) 
Kolopp-Sarda 
[9] 
CD4/CD8 > 2.5 and 
CD103/CD4 < 0.31 
total 93, sarcoidosis 18 96% -  75 70 72 73 
 CD103/CD4 < 0.31 - -  94 18 37 56 
Heron 
[12] 
CD4/CD8 >3 and 
CD103CD4/CD4 <0.2 
total 119, sarcoidosis 56 66 89  58 80 74 69 
 CD103CD4/CD4 < 0.2  - -  94 18 37 56 
Mota 
[10] 
CD103/CD4 < 0.4 total 86, sarcoidosis 41 81 78  98 9 32 54 
Hyldgaard 
[11] 
CD4/CD8 > 3.8 and 
CD103CD4/CD4 < 0.22 
total 107, sarcoidosis 19 42 91  55 86 78 70 
 CD103CD4/CD4 < 0.22  - -  85 28 43 56 
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